Robert Davey, PhD
Boston University School of Medicine
Dept of Microbiology

PhD, University of Adelaide

Dr. Robert Davey, PhD is a currently a Professor of Microbiology at the Boston University School of Medicine. Dr. Davey received his doctorate in Microbiology and Immunology at the University of Adelaide in Australia. He continued his training as a Postdoctoral Fellow at the Howard Hughes Medical Institute and then at the Division of Hematology, both with Dr. James Cunningham at Brigham and Women's Hospital and Harvard Medical School.

Dr. Davey's first academic appointment was as an Instructor in Medicine at Harvard. He then held an Assistant Professor position which he got promoted to Adjunct Associate Professor at the Department of Microbiology and Immunology at the University of Texas Medical Branch.

Dr. Davey was also a Ewing Halsell Scholar and Scientist at the Department of Virology and Immunology at the Texas Biomedical Research Institute. As a Scientist at the Texas Biomedical Research Institute, Dr. Davey's work was focused on identification of cellular factors important for establishing infection by filovirus and bunyaviruses. His work has culminated in a deeper understanding of the entry and cell signaling pathways that are used by these viruses to penetrate the cell membrane and establish infection. His work with Ebolavirus has been published in the high-impact journals PLoS Pathogens, PNAS and a new article on host factor dependence in Science that was featured on the cover page. Dr. Davey’s group works collaboratively with a number of groups providing sophisticated molecular biology and cell biology techniques for the study of pathogenic viruses including Ebolavirus for which the lab mainly works. He has developed high throughput screening techniques for Ebolavirus. He also performs contract work testing drugs and compounds for ebolavirus infection inhibition. His team is well trained in ABSL4 procedures and have been working with Ebolavirus since 2006.

From 2015-2017, Dr. Davey held the role of Interim Chair in the Department of Virology and Immunology at the Texas Biomedical Research Institute. He is also Director of ABSL4 at the Texas Biomedical Research Institute.

Boston University
National Emerging Infectious Disease Lab

Boston University School of Medicine
Evans Center for Interdisciplinary Biomedical Research

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences

2015 San Antonio business journal: Outstanding medical researcher, Healthcare heroes awards
2005 UTMB Graduate school teaching award

Antiviral Lead Identification to Treat Filovirus Infections
08/12/2019 - 07/31/2023 (Subcontract PI)
Purdue University NIH NIAID

STTR Phase I: Aminomethyl benzamides as novel anti Ebola agents
08/16/2019 - 07/31/2022 (Subcontract PI)
Chicago BioSolutions, Inc. NIH NIAID

Neutralization and binding of antibody to virus by Regeneron antibodies
07/08/2020 - 06/30/2022 (Subcontract PI)
Regeneron Pharmaceuticals, Inc. HHS ASPR BARDA

Structural and Functional Characterization of the Ebola Virus Replication Complex (Core C)
07/01/2019 - 06/30/2021 (Subcontract PI)
The Washington University NIH NIAID

Structural and Functional Characterization of the Ebola Virus Replication Complex
07/01/2018 - 06/30/2021 (Subcontract PI)
The Washington University NIH NIAID

HTS for identification and evaluation of efficacy for therapeutics against SARS-CoV-2 infection
05/01/2020 - 04/30/2021 (Subcontract PI)
President & Fellows of Harvard College on behalf of Harvard Medical School China Evergrande Gr

Emerging virus-host cell protein interaction networks
08/01/2018 - 03/31/2021 (Subcontract PI)
Purdue University NIH NIAID

Small molecule inhibitors of Ebola virus polymerase function
08/01/2018 - 01/31/2021 (Subcontract PI)
Georgia State University NIH NIAID

Advanced development of a viral entry inhbitor as a therapeutic for arenavirus hemorrhagic fever
03/01/2020 - 12/31/2020 (Subcontract PI)
Kineta, Inc. NIH NIAID

Modeling Filovirus Infection of and Trafficking through Skin
08/01/2018 - 07/31/2020 (Subcontract PI)
The University of Iowa NIH NIAID


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Cooper L, Schafer A, Li Y, Cheng H, Medegan Fagla B, Shen Z, Nowar R, Dye K, Anantpadma M, Davey RA, Thatcher GRJ, Rong L, Xiong R. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Oct 08; 63(19):11085-11099. PMID: 32886512
  2. Luthra P, Anantpadma M, De S, Sourimant J, Davey RA, Plemper RK, Basler CF. High-Throughput Screening Assay to Identify Small Molecule Inhibitors of Marburg Virus VP40 Protein. ACS Infect Dis. 2020 10 09; 6(10):2783-2799. PMID: 32870648
  3. Lane TR, Massey C, Comer JE, Freiberg AN, Zhou H, Dyall J, Holbrook MR, Anantpadma M, Davey RA, Madrid PB, Ekins S. Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig. Antiviral Res. 2020 09; 181:104863. PMID: 32682926
  4. Gaisina IN, Peet NP, Wong L, Schafer AM, Cheng H, Anantpadma M, Davey RA, Thatcher GRJ, Rong L. Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections. J Med Chem. 2020 07 09; 63(13):7211-7225. PMID: 32490678
  5. Pavlovich SS, Darling T, Hume AJ, Davey RA, Feng F, Mühlberger E, Kepler TB. Egyptian Rousette IFN-? Subtypes Elicit Distinct Antiviral Effects and Transcriptional Responses in Conspecific Cells. Front Immunol. 2020; 11:435.View Related Profiles. PMID: 32231668
  6. Yurdakul C, Avci O, Matlock A, Devaux AJ, Quintero MV, Ozbay E, Davey RA, Connor JH, Karl WC, Tian L, Ünlü MS. High-Throughput, High-Resolution Interferometric Light Microscopy of Biological Nanoparticles. ACS Nano. 2020 02 25; 14(2):2002-2013.View Related Profiles. PMID: 32003974
  7. Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection. PLoS Negl Trop Dis. 2019 11; 13(11):e0007890. PMID: 31751347
  8. Wu Y, Pons V, Noël R, Kali S, Shtanko O, Davey RA, Popoff MR, Tordo N, Gillet D, Cintrat JC, Barbier J. DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses. ACS Med Chem Lett. 2019 Aug 08; 10(8):1140-1147. PMID: 31413797
  9. Lane T, Anantpadma M, Freundlich JS, Davey RA, Madrid PB, Ekins S. The Natural Product Eugenol Is an Inhibitor of the Ebola Virus In Vitro. Pharm Res. 2019 May 17; 36(7):104. PMID: 31101988
  10. Anantpadma M, Lane T, Zorn KM, Lingerfelt MA, Clark AM, Freundlich JS, Davey RA, Madrid PB, Ekins S. Ebola Virus Bayesian Machine Learning Models Enable New in Vitro Leads. ACS Omega. 2019 Jan 31; 4(1):2353-2361. PMID: 30729228
Showing 10 of 88 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 88 publications over 24 distinct years, with a maximum of 8 publications in 2006 and 2018

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Junin virus
Lassa Fever
Contact for Mentoring:

620 Albany Street
Boston MA 02118
Google Map

Davey's Networks
Click the "See All" links for more information and interactive visualizations
Media Mentions
Similar People
Same Department